There are five pilot studies within the iHelp designed to help test and validate the personalised healthcare solution developed in the project. Pilot settings cover from community based (general population) to hospital based (patients). All pilots provide different aspects in relation to disease prevention, personalised health monitoring and decision support. More specifically, Pilot#1 (UNIMAN) focuses on pancreatic cancer risk prediction and risk mitigation. In the risk mitigation process, biomarkers will be assessed and be used as part of motivational change in health habits. Pilot#2 (FPG) focuses on predict outcomes and toxicity using real-world data (RWD) analysis approach. Data on Patient Reported Experience Measures (PREMs) and Patien...
Pancreatic cancer (PC) survival is poor, as detection usually occurs late, when treatment options ar...
Background: Pancreatic cancer is the most aggressive and the most deadly type of cancer. It is the f...
The survival duration for pancreatic cancer is short. Given its low lifetime risk (1.5%), establishe...
Five pilot studies will be carried out as part of iHelp, to help test and validate the solution deve...
This document represents the assessment of the iHelp approaches by showing the proposed data collect...
The objective of this deliverable is to define personalised recommendations in terms of prevention a...
This report summarizes the actions performed under Task 5.1 - “Techniques for early risk identificat...
iHelp aims to early detect and mitigate the risks associated with Pancreatic Cancer applying advance...
iHelp aims to early detect and mitigate the risks associated with Pancreatic Cancer applying advance...
(1) Background: There are few studies on people at high risk for clinical pancreatic cancer (PC). We...
We are developing an online education programme called Informed Health Choices-Cancer (IHC-C) based ...
Introduction: Overall cancer survival has increased over the recent decades, but the dismal surviva...
There is no reliable screening tool to identify people with high risk of developing pancreatic cance...
Abstract for the Exploring New Possibilities Doctoral College Conference outlining the potential of ...
Anwar E Ahmed,1,2 Faris S Alzahrani,2 Ahmed M Gharawi,2 Salman A Alammary,2 Fahad H Almijmaj,2 Fahad...
Pancreatic cancer (PC) survival is poor, as detection usually occurs late, when treatment options ar...
Background: Pancreatic cancer is the most aggressive and the most deadly type of cancer. It is the f...
The survival duration for pancreatic cancer is short. Given its low lifetime risk (1.5%), establishe...
Five pilot studies will be carried out as part of iHelp, to help test and validate the solution deve...
This document represents the assessment of the iHelp approaches by showing the proposed data collect...
The objective of this deliverable is to define personalised recommendations in terms of prevention a...
This report summarizes the actions performed under Task 5.1 - “Techniques for early risk identificat...
iHelp aims to early detect and mitigate the risks associated with Pancreatic Cancer applying advance...
iHelp aims to early detect and mitigate the risks associated with Pancreatic Cancer applying advance...
(1) Background: There are few studies on people at high risk for clinical pancreatic cancer (PC). We...
We are developing an online education programme called Informed Health Choices-Cancer (IHC-C) based ...
Introduction: Overall cancer survival has increased over the recent decades, but the dismal surviva...
There is no reliable screening tool to identify people with high risk of developing pancreatic cance...
Abstract for the Exploring New Possibilities Doctoral College Conference outlining the potential of ...
Anwar E Ahmed,1,2 Faris S Alzahrani,2 Ahmed M Gharawi,2 Salman A Alammary,2 Fahad H Almijmaj,2 Fahad...
Pancreatic cancer (PC) survival is poor, as detection usually occurs late, when treatment options ar...
Background: Pancreatic cancer is the most aggressive and the most deadly type of cancer. It is the f...
The survival duration for pancreatic cancer is short. Given its low lifetime risk (1.5%), establishe...